🇺🇸 Clopidogrel+Aspirin in United States
60 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 60
Most-reported reactions
- Acute Kidney Injury — 6 reports (10%)
- Akinesia — 6 reports (10%)
- Cardiac Failure — 6 reports (10%)
- Decreased Appetite — 6 reports (10%)
- Ejection Fraction Decreased — 6 reports (10%)
- Hepatic Steatosis — 6 reports (10%)
- Iron Deficiency Anaemia — 6 reports (10%)
- Mitral Valve Incompetence — 6 reports (10%)
- Oedema Peripheral — 6 reports (10%)
- Peripheral Swelling — 6 reports (10%)
Other Cardiovascular approved in United States
Frequently asked questions
Is Clopidogrel+Aspirin approved in United States?
Clopidogrel+Aspirin does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Clopidogrel+Aspirin in United States?
Seoul National University Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.